Foundation Medicine Inc. will use its $42.5 million series B round to expand sales of its first cancer diagnostic and to launch a second next year.

New investors Casdin Capital Management; Deerfield Management; Redmile Group; Laboratory Corp. of America Holdings (NYSE:LH); Roche Venture Fund; WuXi Corporate Venture Fund; and an undisclosed public investment fund joined existing investors Third Rock Ventures; Google Ventures; and Kleiner Perkins Caufield & Byers